Clinical trials
System Lupus Erythematosus(SLE) clinical trials
Below are recruiting system lupus erythematosus(sle) clinical trials, each written for real people, not researchers. We’re tracking 223 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07109986RecruitingPhase 1
Study of UB-VV410 for active lupus or lupus nephritis
This trial tests a new treatment, UB-VV410, for people with active systemic lupus erythematosus (SLE) or lupus nephritis (kidney inflammation caused by lupus) that hasn't responded to standard treatments. It aims to see if this therapy can help control the disease.
NanjingAges 18–65 - NCT07123519RecruitingPhase 1
YTS109 cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
TianjinAges 18–65 - NCT07148115Recruiting
Pregnancies before lupus diagnosis
This trial studies women who had at least one pregnancy before being diagnosed with lupus. It aims to understand how lupus may have affected those pregnancies.
Aïn Taya, Algiers ProvinceAges 18–55 - NCT07150000Recruiting
Rheumatic disease research study for patients and healthy volunteers
This study is for people with certain rheumatic conditions (like arthritis, lupus, or vasculitis) and for healthy volunteers. It aims to learn more about these diseases and improve how they are treated.
Bonn, North Rhine-WestphaliaAges 18 years+ - NCT07174843RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07177911RecruitingPhase 1
Study of CC312 for moderate to severe lupus
This trial tests a new medicine called CC312 for people with moderate to severe lupus (SLE) that hasn't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
Chengdu, SichuanAges 18–65 - NCT07185269RecruitingPhase 1/Phase 2
Testing 626 for lupus: a phase 1/2 study
This trial tests a new drug called 626 for people with systemic lupus erythematosus (SLE). It aims to see if the drug is safe and effective at reducing disease activity.
Beijing, Beijing MunicipalityAges 18–70 - NCT07193810RecruitingEarly Phase 1
CC312 for autoimmune diseases that returned or didn't respond
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
Deyang, SichuanAges 18–65 - NCT07215663RecruitingPhase 1
Cizutamig for active lupus not helped by other treatments
This study tests a new biologic drug called cizutamig for people with active lupus (SLE) who haven't gotten enough help from standard treatments. The goal is to see if it can safely reduce disease activity.
BeijingAges 18–75 - NCT07215754Recruiting
Real-world study of anifrolumab for active lupus
This study tracks how well anifrolumab works and how safe it is for people with active lupus. It's a real-world look at the drug's effects, so no additional treatments or tests are required beyond what your doctor already prescribes.
PisaAges 18 years+ - NCT07219563RecruitingPhase 1
Alnuctamab for hard-to-treat lupus (LATTE Study)
This trial tests a new drug called alnuctamab for people with lupus (SLE) that hasn't responded to multiple standard treatments. It aims to see if targeting certain immune cells can reduce lupus activity.
New York, New YorkAges 18–60 - NCT07225543RecruitingPhase 2
Study of 2-HOBA for women with lupus
This trial tests whether a natural compound called 2-HOBA can help women with lupus who also have mildly high blood pressure. It aims to improve blood vessel health and reduce inflammation.
Nashville, TennesseeAges 18 years+ - NCT07233642RecruitingPhase 1
Fast CD19 CAR-T therapy for lupus not helped by standard treatment
This trial tests a quick-made CAR-T cell therapy for children and adults with active lupus who haven't gotten better with standard drugs. The goal is to see if targeting a protein called CD19 on certain immune cells can calm the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT07236762RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
BengbuAges 18–65 - NCT07236801RecruitingPhase 1
Cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Xuzhou, JiangsuAges 18–65 - NCT07246096RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
ShanghaiAges 18–70 - NCT07249060Recruiting
Interferon levels in cancer and autoimmune disease patients
This study looks at a protein called interferon in the blood of people with cancer who are starting immunotherapy, and people with certain autoimmune diseases (such as lupus, Sjögren's syndrome, scleroderma, or inflammatory myopathy). The goal is to compare interferon patterns and better understand immune responses.
Pamplona, NavarreAges 18 years+ - NCT07515014RecruitingPhase 2
Testing E6742 in Systemic Lupus Erythematosus
This study tests a new medicine called E6742 to help people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. Researchers want to see if this drug can reduce lupus symptoms and disease activity.
Bengbu, AnhuiAges 18–75 - NCT07274059RecruitingEarly Phase 1
CAR-T cell therapy from cord blood for lupus
This trial tests a new CAR-T cell treatment made from donor umbilical cord blood for people with lupus that hasn't improved with at least two standard treatments. The goal is to see if it can help control disease activity.
Yancheng, JiangsuAges 18–75 - NCT07278609Recruiting
Safer medication use for older adults with rheumatic conditions
This study tests a program to help doctors choose safer medications for people aged 60 and older who have arthritis or other rheumatic conditions. It aims to reduce the use of potentially harmful drugs and improve overall medication safety.
Montreal, QuebecAges 60 years+ - NCT07299422RecruitingPhase 2
Study of SHR-2173 for people with lupus
This trial tests a new drug called SHR-2173 for people with active lupus. It aims to see if it can reduce disease activity when taken with standard treatments.
Beijing, Beijing MunicipalityAges 18–65 - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT07318259RecruitingPhase 1
Study of a new CAR-T therapy for lupus
This trial tests a fast-acting CAR-T therapy that targets BCMA and CD70 proteins to treat lupus. It may help people with moderate-to-severe lupus that hasn't improved with standard treatments.
Nanjing, JiangsuAges 18 years+ - NCT07330245Recruiting
Study of anifrolumab for lupus patients needing treatment
This study looks at how well anifrolumab works for people with systemic lupus erythematosus (SLE) who are starting it for the first time. It aims to see if patients can achieve a low disease activity state (LLDAS5) after treatment.
Monserrato, CAAges Any age
Hear when a new System Lupus Erythematosus(SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for system lupus erythematosus(sle)?
- Yes. Clin2 currently lists 223 recruiting system lupus erythematosus(sle) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a system lupus erythematosus(sle) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a system lupus erythematosus(sle) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.